CP-751,871 Treatment For Patients With Multiple Myeloma

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Previously treated multiple myeloma with a quantifiable serum (M spike ≥ 1 g/dL) and/or urine (≥ 200 mg/24-hr) paraprotein

• Adequate bone marrow, renal, liver and cardiac function

• Eastern Cooperative Oncology Group [ECOG] performance status less than or equal to 2

Exclusion Criteria:

• Prior allogeneic stem cell transplant (alloSCT)

• Myelosuppressive chemotherapy or immunotherapy within 3 weeks prior to treatment with CP-751,871

• Prior organ allograft

• Concurrent use of insulin, oral hypoglycemic medication, growth hormone (GH), or growth hormone inhibitors

• Female patients who are pregnant or lactating